CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 22 enrolled
Drug / intervention
axitinib +2 moredrug
Likely dose
axitinib 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00842244
NCT00842244Phase 1Completed
CompareCT.gov

A Phase 1 Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer

Pfizer·interventional·Posted Feb 12, 2009·Updated Nov 27, 2013

In Brief

A Phase 1 clinical trial evaluating axitinib, capecitabine, and 1 other intervention for Stomach Neoplasms and Advanced Gastric Cancer. Completed, enrolled 22 participants across 5 sites in 2 countries.

Detailed Summary

The purpose of this study is to determine the safe and tolerable dose of axitinib given together with cisplatin and capecitabine in patients with advanced gastric cancer who have not received prior chemotherapy for their advanced cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStomach Neoplasms, Advanced Gastric Cancer
CountriesJapan, South Korea
Collaborators--

Timeline

Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 12, 2009
Enrollment StartApr 1, 2009
Primary CompletionDec 1, 2009
Study CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.4 years ago

Interventions

axitinibdrug

Twice daily oral dose of axitinib continuously depending upon side effects observed. Starting dose is 5mg twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.

capecitabinedrug

Given orally twice daily for 14 days followed by 7 days of drug free period. Starting dose is 1000mg/m\^2 twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.

cisplatindrug

Given through a vein on Day 1 of every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed. The starting dose is 80 mg/m\^2 on day 1.